AbCellera (ABCL) stock soared 32% after its menopause treatment ABCL635 achieved Phase 2 trial goals, reducing hot flashes without serious side effects. The post AbCellera (ABCL) Stock Surges 32% on Positive Menopause Treatment Results appeared first on Blockonomi.